The Small Print That Could Cost You: HRT, Life Insurance, and the Disclosure Trap British Women Don't Know They're In
When Karen, 52, from Edinburgh, finally got her HRT prescription after two years of struggling through perimenopause, she felt like she'd won a small battle. Her sleep improved. Her anxiety lifted. She felt like herself again. A few months later, she mentioned it to her financial adviser during an annual review — and that's when things got complicated.
"He told me I needed to declare it on my income protection policy," she says. "I had no idea. I thought HRT was just... hormones. Like the pill. I didn't think it counted as a medical thing I'd need to tell my insurer about."
Karen's story is far more common than the financial or medical industries would like to admit. Across the UK, women are navigating a disclosure minefield that most of them don't even know exists — one where the decision to treat a natural biological process with prescribed medication can have real consequences for their insurance cover, their premiums, and in some cases, their ability to get cover at all.
What the Law Actually Requires
Let's start with the basics, because there's a lot of confusion here.
Under UK insurance law, you are required to answer all questions on an insurance application honestly and in full. This is known as the duty of fair presentation (for new policies taken out after 2016 under the Insurance Act). The insurer sets the questions — and critically, you are only required to disclose what they specifically ask.
Most life insurance and critical illness applications will ask about current prescribed medications and any diagnosed medical conditions. HRT — being a prescription medication — typically falls within scope of that question. Failing to disclose it, even unintentionally, can give an insurer grounds to void a claim later.
"The problem isn't that women are being dishonest," says financial adviser Claire Hutchinson, who specialises in protection insurance. "It's that they genuinely don't know that a prescription they think of as routine needs to be declared. They associate disclosure with serious illness, not with menopause treatment."
How Insurers Are Actually Treating HRT
Here's where it gets more nuanced — and more infuriating.
Not all insurers treat HRT the same way. Some will simply note the prescription and apply no additional loading to your premium. Others will ask follow-up questions about your reasons for taking it, your symptom history, and any related conditions. A small number may apply a premium increase or add an exclusion clause, particularly if the application also involves other health factors.
The type of policy matters enormously. Life insurance is generally more straightforward — HRT alone is unlikely to significantly affect a standard term life policy for most women. It's income protection and critical illness cover where things can get thornier.
Income protection policies pay out if you're unable to work due to illness. Some insurers have raised questions about whether menopause-related disability could trigger a claim, and have started building that into their underwriting decisions — which can mean higher premiums or exclusions for menopause-related conditions.
Critical illness cover, meanwhile, pays a lump sum if you're diagnosed with a specified serious condition. The concern here is less about HRT itself and more about what it might indicate — for example, whether a woman's medical history shows cardiovascular risk factors or a family history of certain cancers, both of which can interact with how an insurer views HRT use.
The Chilling Effect on Treatment Decisions
This is where things become genuinely alarming.
Several women we spoke to for this article admitted that concerns about insurance implications had factored into their decision about whether to accept an HRT prescription. One woman, 49, from Birmingham, asked not to be named. "My GP offered me HRT and I asked her whether it would affect my life insurance. She said she didn't know. I ended up not taking it because I was scared of the financial implications. I suffered for another eighteen months unnecessarily."
There is no reliable data on how widespread this is, but campaigners and GPs are increasingly raising the alarm. If women are declining evidence-based treatment for a manageable condition because they fear financial penalties, something has gone badly wrong.
"We absolutely should not have a situation where women are making health decisions based on insurance fears," says Dr. Naomi Ashworth, a GP with a specialist interest in menopause. "HRT, for most women, is safe and effective. The idea that taking it might penalise them financially is deeply troubling."
What About Existing Policies?
If you already have insurance and you've since been prescribed HRT, do you need to tell your insurer?
Generally, no — once a policy is in place, you typically only have a duty to disclose changes if the policy specifically requires it (some income protection policies do have ongoing disclosure clauses, so check your documents). However, if you need to make a claim, the insurer may review your medical records, and any undisclosed prescriptions could become relevant.
The safest approach is to review your existing policies and, if in doubt, speak to an independent financial adviser — not the insurer directly — about what you need to disclose and how.
Shopping the Market: Not All Insurers Are Equal
One of the most important things to know is that underwriting decisions vary significantly between insurers. If one company loads your premium or declines your application because of HRT, another may not.
This is where using an independent broker — rather than going direct — becomes genuinely valuable. A good broker who understands menopause-related disclosures can approach the market on your behalf and find the most favourable terms. Some specialist protection advisers now explicitly advertise experience with menopause-related applications.
The Bigger Picture
The Association of British Insurers (ABI) has stated that insurers should not discriminate unfairly on the basis of gender, and that medical information should only be used where it is relevant and actuarially justified. But without specific guidance on menopause and HRT, individual insurers continue to make their own underwriting decisions — often with limited consistency.
Campaigners are calling for the ABI to issue clear guidance specifically addressing HRT disclosure, and for the financial services regulator (the FCA) to examine whether current practices are creating a chilling effect on women's healthcare decisions.
Until that happens, the burden falls on individual women — most of whom have no idea this conversation even needs to happen.
Karen from Edinburgh eventually got her income protection policy updated with full disclosure. Her premium went up slightly. "It wasn't as bad as I feared," she says. "But I'm angry that I had to figure all of this out myself. Why isn't anyone telling women about this when they hand over the prescription?"
Why indeed.
